戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ated with substantial mortality despite IABP counterpulsation.
2 to vasopressors or intra-aortic balloon pump counterpulsation.
3  vasopressor agents and intra-aortic balloon counterpulsation.
4 ) requiring intra-aortic balloon pump (IABP) counterpulsation.
5 cluding thrombolysis and intraaortic balloon counterpulsation.
6 rdiac output and may be an ideal setting for counterpulsation.
7  support devices such as intraaortic balloon counterpulsation (7.7%), left ventricular assist device
8 ysis (63% of patients), intra-aortic balloon counterpulsation (86%), and subsequent revascularization
9 data from the first large registry of aortic counterpulsation, a computerized database that incorpora
10           Patients were given 35 h of active counterpulsation (active CP) or inactive counterpulsatio
11 prophylactic intraaortic balloon pump (IABP) counterpulsation after primary percutaneous transluminal
12 atment strategies using intra-aortic balloon counterpulsation and emergency revascularization by perc
13 ity, stabilization with intra-aortic balloon counterpulsation and thrombolysis followed by transfer t
14 early angiography, intra-aortic balloon pump counterpulsation, and early revascularization with PCI o
15 cal ventilatory support, intraaortic balloon counterpulsation, and hemodialysis or ultrafiltration.
16 663 consecutive patients treated with aortic counterpulsation at 250 medical centers worldwide; 5,495
17                         Intra-aortic balloon counterpulsation augmentation performed after reperfusio
18 oplasty, angioplasty, and sizing balloons as counterpulsation balloons.
19 ddling the aortic annulus and connected to a counterpulsation console-can serve as a temporizing valv
20 oup, 301 patients) or no intraaortic balloon counterpulsation (control group, 299 patients).
21 sation for 68 hrs or no intra-aortic balloon counterpulsation (control).
22               The use of intraaortic balloon counterpulsation did not significantly reduce 30-day mor
23 o assess the effects of intra-aortic balloon counterpulsation during sepsis with increasing risk of d
24                            Enhanced external counterpulsation (EECP) has been shown to reduce angina
25 y assessed the benefits of enhanced external counterpulsation (EECP) in the treatment of patients wit
26                            Enhanced external counterpulsation (EECP) is a noninvasive, pneumatic tech
27 s to examine the effect of enhanced external counterpulsation (EECP) on endothelial function.
28  anti-ischemic benefits of enhanced external counterpulsation (EECP) remain unknown.
29 ent evidence suggests that enhanced external counterpulsation (EECP) therapy may improve symptoms and
30 ess safety and efficacy of enhanced external counterpulsation (EECP).
31                            Enhanced external counterpulsation enhances peripheral endothelial functio
32 n randomized to receive intra-aortic balloon counterpulsation for 68 hrs or no intra-aortic balloon c
33 ower doses of bacteria, intra-aortic balloon counterpulsation had no significant effects on survival
34                         Intra-aortic balloon counterpulsation (IABC) can improve post-myocardial infa
35                         Intra-aortic balloon counterpulsation (IABC) is an adjunct to revascularizati
36 myocardial infarction to intraaortic balloon counterpulsation (IABP group, 301 patients) or no intraa
37  and outcomes with early intraaortic balloon counterpulsation (IABP) in patients presenting with card
38 c therapy (TT) and intra-aortic balloon pump counterpulsation (IABP) on in-hospital mortality rates o
39 s between the number of intra-aortic balloon counterpulsation (IABP) procedures performed at a given
40 data on indications for intra-aortic balloon counterpulsation (IABP) use, patient demographics, conco
41 ial benefit of combining intraaortic balloon counterpulsation (IABP) with thrombolysis for acute myoc
42 s, ventilatory support, intra-aortic balloon counterpulsation (IABP), percutaneous transluminal coron
43 highest bacterial dose, intra-aortic balloon counterpulsation improved survival time (23.4 +/- 10 hrs
44                            Enhanced external counterpulsation improves symptoms and exercise toleranc
45 fied prediction models (Intra-Aortic Balloon Counterpulsation in Acute Myocardial Infarction Complica
46 (Prospective Evaluation of Enhanced External Counterpulsation in Congestive Heart Failure) study asse
47 le ventricle (SMV) was configured to produce counterpulsation in the thoracic aorta similar to that o
48 mber of alternatives to intra-aortic balloon counterpulsation in the treatment of anticipated and est
49 logical benefits achieved by the use of IABP counterpulsation in these situations, all the recent tri
50 ive counterpulsation (active CP) or inactive counterpulsation (inactive CP) over a four- to seven-wee
51                            Enhanced external counterpulsation is a viable treatment option for select
52 nternational guidelines, intraaortic balloon counterpulsation is considered to be a class I treatment
53                         Intra-aortic balloon counterpulsation is employed in patients with impaired l
54                            Enhanced external counterpulsation led to symptomatic improvement (>/=1 Ca
55 ion technique, and operator experience, IABP counterpulsation may be successfully employed for a wide
56 f the physiological premises of intra-aortic counterpulsation may underpin the rationale to maintain
57  no pLVAD support (intra-aortic balloon pump counterpulsation, n = 6; no support, n = 7).
58 ter studies, the use of intra-aortic balloon counterpulsation, percutaneous ventricular assist device
59 rs, iron chelation, and intra-aortic balloon counterpulsation, perhaps should be retired.
60 ty included preoperative intraaortic balloon counterpulsation, preoperative serum bilirubin of >1.0 m
61 th a low cardiac index, intra-aortic balloon counterpulsation prolongs survival time and lowers vasop
62                            Enhanced external counterpulsation reduced angina symptoms and extended ti
63                            Enhanced external counterpulsation reduces angina and extends time to exer
64 cardial revascularization, enhanced external counterpulsation, spinal cord stimulation, or sympathect
65                             The technique of counterpulsation, studied for almost one-half century no
66 h and broadened indications for intra-aortic counterpulsation, the current indications, associated co
67 ilable devices-the intra-aortic balloon pump counterpulsation, the Impella system, the TandemHeart, a
68 ization and use of intra-aortic balloon pump counterpulsation therapy, the prognosis of patients with
69 cal usage of intraaortic balloon pump (IABP) counterpulsation, there is a paucity of randomized trial
70 ulticenter, randomized controlled trial, the Counterpulsation to Reduce Infarct Size Pre-PCI Acute My
71 ese beneficial effects, intra-aortic balloon counterpulsation was associated with an increase in bloo
72    However, although the concept of external counterpulsation was introduced almost four decades ago,
73 ovascular support using intra-aortic balloon counterpulsation was investigated in a hypodynamic, mech
74                          Intraaortic balloon counterpulsation was performed in 86 percent of the pati